KRYS — Krystal Biotech, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711279 ·
Last close
$345.82
Market Cap
$10.24B
52W High
$382.54
52W Low
$159.24
ADV30
256,517
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 119,222,000 | 112,785,000 | 58,417,000 | 54,768,000 | 1,500,648,000 | 427,740,000 | 141,522,000 |
| Mar 2026 | 116,357,000 | 110,034,000 | 53,689,000 | 55,932,000 | 1,396,967,000 | 501,313,000 | 120,238,000 |
| Dec 2025 | 107,105,000 | 100,513,000 | 44,270,000 | 51,400,000 | 1,333,794,000 | 496,304,000 | 114,234,000 |
| Sep 2025 | 97,800,000 | 93,537,000 | 41,374,000 | 79,365,000 | 1,240,094,000 | 392,604,000 | 102,218,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$272,338,000
Investing CF
$-218,290,000
Financing CF
$23,969,000
CapEx
$-14,556,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.98
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$134,863,000
Inventory
$45,556,000
Receivables
$138,662,000
ST Investments
$417,891,000
EBIT TTM
$197,750,000
Pretax Income TTM
$226,619,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$440,484,000
EBITDA
$199,292,992
Free Cash Flow
$151,739,744
Enterprise Value
$9,434,017,792
Total Cash
$845,630,976
Total Debt
$8,853,000
Shares Out
29,598,836
Trailing EPS
$7.98
Book Value
$45.92
ROE
20.1%
ROA
9.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 389,130,000 | 161,295,000 | 204,831,000 | 1,333,794,000 | 114,234,000 | 1,219,560,000 | 200,865,000 |
| Dec 2024 | 290,515,000 | 103,248,000 | 89,159,000 | 1,055,838,000 | 109,458,000 | 946,380,000 | 123,420,000 |
| Dec 2023 | 50,699,000 | -97,117,000 | 10,932,000 | 818,355,000 | 39,714,000 | 778,641,000 | -88,804,000 |
| Dec 2022 | 0 | -120,196,000 | -139,975,000 | 558,450,000 | 36,219,000 | 522,231,000 | -100,569,000 |
TTM Snapshot
Revenues TTM
$180,580,000
NetIncome TTM
$113,810,000
OpCashFlow TTM
$0
Assets (Latest)
$1,333,794,000
Forward EPS
$9.40
Max Pain — expiry 2027-02-19
max pain strike: $340.00 · spot: $338.58 · call oi: 169 · put oi: 1,005
Expected Move to 2027-02-19:
±$106.05
(31.32%) —
implied range
$232.53 –
$444.63
· ATM straddle on $340.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $10.70B | $189.68 | — |
| KYMR | Kymera Therapeutics, Inc. | $9.21B | $111.95 | — |
| TECH | BIO-TECHNE Corp | $11.39B | $72.61 | — |
| QGEN | QIAGEN N.V. | $9.12B | $44.18 | — |
| IBRX | ImmunityBio, Inc. | $8.95B | $8.44 | — |
News headlines (Yahoo Finance, 1h cache)
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
2026-09-03 15:49 · Yahoo
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
2026-09-03 12:00 · Yahoo
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
2026-09-02 15:30 · Yahoo
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says
2026-08-14 15:11 · Yahoo
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
2026-08-14 11:55 · Yahoo
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
2026-08-11 01:32 · Yahoo
J&J pharma leader to retire; Krystal slumps on gene therapy miss
2026-08-04 10:20 · Yahoo
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ...
2026-08-03 21:00 · Yahoo
Krystal Biotech Q2 Earnings Call Highlights
2026-08-03 14:04 · Yahoo
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts
2026-08-03 12:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.